Kucukoner Mehmet, Isikdogan Abdurrahman, Yaman Sebnem, Gumusay Ozge, Unal Olcun, Ulas Arife, Elkiran Emir T, Kaplan Muhammed A, Ozdemir Nuriye, Inal Ali, Urakci Zuhat, Buyukberber Suleyman
Department of Medical Oncology, Dicle University, Diyarbakir, Turkey.
Asian Pac J Cancer Prev. 2012;13(8):3973-6. doi: 10.7314/apjcp.2012.13.8.3973.
The aim of this study was to evaluate the efficacy and toxicity of long-term, low-dose oral etoposide as an advanced treatment option in patients with platinum resistant epithelial ovarian cancer.
For the purposes of this study, 51 patients with histologically-confirmed, recurrent or metastatic platinum-resistant epithelial ovarian cancer (EOC) treated at six different centers between January 2006 and January 2011 were retrospectively evaluated. Patients were treated with oral etoposide (50 mg/day for a cycle of 14 days, repeated every 21 days).
Among the 51 platinum-resistant patients, 17.6% demonstrated a partial response and 25.5% a stable response. The median progression-free survival (PFS) was 3.9 months (95% CI, 2.1-5.7), while the median overall survival was 16.4 months (11.8-20.9). No significant relationship was observed between the pre-treatment CA 125 levels, post-treatment CA-125 levels and the treatment response rates (p=0.21). Among the 51 patients who were evaluated in terms of toxicity, grade 1 or 4 hematologic toxicity was observed in 19 (37.3%); and grade 1-4 gastrointestinal toxicity occurred in 15 patients (29.4%).
Chronic low-dose oral etoposide treatment is generally effective and well-tolerated in platinum-resistant ovarian cancer patients.
本研究旨在评估长期低剂量口服依托泊苷作为铂耐药上皮性卵巢癌患者晚期治疗方案的疗效和毒性。
为开展本研究，对2006年1月至2011年1月期间在六个不同中心接受治疗的51例经组织学确诊的复发性或转移性铂耐药上皮性卵巢癌（EOC）患者进行了回顾性评估。患者接受口服依托泊苷治疗（50mg/天，疗程14天，每21天重复一次）。
在51例铂耐药患者中，17.6%表现出部分缓解，25.5%表现为病情稳定。无进展生存期（PFS）中位数为3.9个月（95%CI，2.1 - 5.7），总生存期中位数为16.4个月（11.8 - 20.9）。治疗前CA 125水平、治疗后CA - 125水平与治疗缓解率之间未观察到显著相关性（p = 0.21）。在51例接受毒性评估的患者中，19例（37.3%）观察到1级或4级血液学毒性；15例患者（29.4%）发生1 - 4级胃肠道毒性。
慢性低剂量口服依托泊苷治疗对铂耐药卵巢癌患者总体有效且耐受性良好。
